Pharma and Biotech
| Latest | F'cast | |
|---|---|---|
| Div Yield | 0.0% | 0.0% |
| Div Cover | n/a | n/a |
| Op Mrgn | n/a | n/a |
| ROCE | n/a |
| Latest | F'cast | |
|---|---|---|
| P/E | n/a | n/a |
| PEG | n/a | n/a |
| Pr/Revenue | n/a | n/a |
| Pr/Book | 7.1 |
| Latest | F'cast | |
|---|---|---|
| Revenue | n/a | n/a |
| PBT | n/a | n/a |
| EPS | n/a | n/a |
| DPS | n/a | n/a |
| Year Ending | Revenue (£m) | Pre-tax (£m) | EPS | P/E | PEG | EPS Grth. | Div | Yield |
|---|---|---|---|---|---|---|---|---|
| 31-Dec-20 | 0.52 | (0.45) | (0.65)p | n/a | n/a | n/a | n/a | 0.0% |
| 31-Dec-21 | 0.22 | (0.95) | (1.36)p | n/a | n/a | n/a | n/a | 0.0% |
| 31-Dec-22 | 0.54 | (2.70) | (2.61)p | n/a | n/a | n/a | n/a | 0.0% |
| 31-Dec-23 | 0.59 | (3.12) | (3.00)p | n/a | n/a | n/a | n/a | 0.0% |
| 31-Dec-24 | n/a | (1.45) | (0.12)p | n/a | n/a | n/a | n/a | 0.0% |
a. Based on UK GAAP presentation of accounts - includes discontinued activities
| Research and Development Update – Q4 2025 | 22-Dec-2025 | 07:00 | RNS |
| Research and Development Update – Q4 2025 | 22-Dec-2025 | 07:00 | RNS |
| SVN-015 accepted into US NIDA funded programme | 03-Dec-2025 | 07:00 | RNS |
| Research and Development Update – Q4 2025 | 22-Dec-2025 | ShareCast |
| Graft Polymer to buy Awakn in £4.98m deal | 16-Dec-2024 | ShareCast |
No deals were found in the last 28 days.
| Currency | UK Pounds |
| Share Price | 0.32p |
| Change Today | 0.010p |
| % Change | 3.23 % |
| 52 Week High | 0.39 |
| 52 Week Low | 0.12 |
| Volume | 53,023,351 |
| Shares Issued | 6,806m |
| Market Cap | £21.78m |
| Value |
|
|---|
| Price Trend |
|
|---|
| Income | ![]() |
|---|
| Growth | ![]() |
|---|
| No dividends found |
| Time | Volume / Share Price |
| 16:35 | 900,499 @ 0.32p |
| 16:35 | 900,000 @ 0.32p |
| 16:35 | 499 @ 0.32p |
| 16:29 | 375,000 @ 0.32p |
| 16:27 | 424,022 @ 0.33p |
| CEO | Anthony Tennyson |
| Chair | Dennis Purcell |
You are here: research